Antiangiogenic activity of the MDM2 antagonist nutlin-3

Circulation Research

Volumn 100, Issue 1, 2007, Pages 61-69

  Secchiero, Paola ^a   Corallini, Federica ^a   Gonelli, Arianna ^a   Dell'Eva, Raffaella ^b   Vitale, Marco ^c   Capitani, Silvano ^a   Albini, Adriana ^d   Zauli, Giorgio ^e  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d IRCCS MULTIMEDICA   (Italy)

^e UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Angiogenesis; Cell cycle; Endothelial cells; Signaling pathways

Indexed keywords

ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN 15; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DOXORUBICIN; ENZYME INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LY 29400; MATRIGEL; NUTLIN 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MIGRATION INHIBITION; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UPREGULATION; VASCULAR ENDOTHELIUM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CAPILLARIES; CELL CYCLE; CELL MOVEMENT; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; IMIDAZOLES; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; NF-KAPPA B; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33846087742     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000253975.76198.ff     Document Type: Article

References (30)

1. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000;77:81-137.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307-310.
3. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2:594-604.
4. Gostissa M, Hofmann TG, Will H, Del Sal G. Regulation of p53 functions: let's meet at the nuclear bodies. Curr Opin Cell Biol. 2003;15:351-357.
5. Roger L, Gadea G, Roux P. Control of cell migration: a tumour suppressor function for p53? Biol Cell. 2006;98:141-152.
6. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol. 2003;13:49-58.
7. Stommel JM, Wahl GM. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 2004;23:1547-1556.
8. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu E. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844-848.
9. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 2005;65:1918-1924.
10. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC. Vassilev LT. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A. 2005;103:1888-1893.
11. Vassilev LT. p53 activation by small molecules: application in oncology. J Med Chem. 2005;48:4491-4499.
12. Folkman J. Angiogenesis-dependent diseases. Semin Oncol. 2001;28:536-542.
13. Carmeliet P. Angiogenesis in health and disease. Nature Med. 2003;9:653-660.
14. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2:727-739.
15. Ferrari N, Pfeffer U, Dell'Eva R, Ambrosini C, Noonan DM, Albini A. The transforming growth factor-B family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-Hydroxyphenyl) retinamide. Clin Cancer Res. 2005;11:4610-4619.
16. Donà M, Dell'Aica I, Calabrese F, Benelli R, Morini M, Albini A, Garbisa S. Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J Immunol. 2003;170:4335-4341.
17. Secchiero P, Gonelli A, Carnevale E, Corallini F, Rizzardi C, Zacchigna S, Melato M, Zauli G. Evidence for a pro-angiogenic activity of TNF-related apoptosis-inducing ligand (TRAIL). Neoplasia. 2004;6:354-373.
18. Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P. TNF-related apoptosis-inducing ligand (TRAIL) sequentially up-regulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res. 2003;92:732-740.
19. Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D, Zauli G. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation. 2003;107:2250-2256.
20. Yang H, Filipovic Z, Brown D, Breit SN, Vassilev LT. Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol Cancer Ther. 2003;2:1023-1029.
21. Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. J Biol Chem. 2004;279:25535-25543.
22. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol. 1998;8:345-357.
23. Tan M, Wang Y, Guan K, Sun Y. PTGF-β, a type β transforming growth factor (TGF-β) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-β signaling pathway. Proc Natl Acad Sci U S A. 2000;97:109-114.
24. Li PX, Wong J, Ayed A, Ngo D, Brade AM, Arrowsmith C, Austin RC, Klamut H. Placental transforming growth factor-β is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem. 2000;275:20127-20135.
25. Jang TY, Kang HJ, Kim JR, Yang CH. Non-steroidal antiinflammatory drug activated gene (NAG-1) expression is closely related to death receptor-4 and -5 induction, which may explain sulindac sulfide induced gastric cancer cell apoptosis. Carcinogenesis. 2004;25:1853-1858.
26. Wilson LC, Baek SJ, Call A, Eling TE. Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is induced by genistein through the expression of p53 in colorectal cancer cells. Int J Cancer. 2003;105:747-753.
27. Abrams SI. Regulation of tumor progression by anti-neoplastic T cell responses. Cancer Biol Ther. 2004;3:140-146.
28. Orentas RJ, Kohler ME, Johnson BD. Suppression of anti-cancer immunity by regulatory T cells: back to the future. Semin Cancer Biol. 2006;16:137-149.
29. Shirley RB, Kaddour-Djebbar I, Patel DM, Lakshmikanthan V, Lewis RW, Kumar MV. Combination of proteasomal inhibitors lactacystin and MG132 induced synergistic apoptosis in prostate cancer cells. Neoplasia. 2005;7:1104-1111.
30. Arima Y, Nitta M, Kuninaka S, Zhang D, Fujiwara T, Taya Y, Nakao M, Saya H. Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J Biol Chem. 2005;280:19166-19176.